All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

trastuzumab emtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4990	1018448-65-1

Description:

Molecule	Description
Synonyms: trastuzumab-DM1 conjugate trastuzumab emtansine ado-trastuzumab emtansine kadcyla PRO132365 trastuzumab-MCC-DM1 T-DM1 huN901-DM1	Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination. Molecular weight: Formula: (C47H62ClN4O14S)3-4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
12	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Sept. 20, 2013	PMDA	Chugai Pharmaceutical Co., Ltd
Feb. 22, 2013	FDA	GENENTECH
Nov. 15, 2013	EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	1000.32	23.24	604	26149	156011	90445683
Metastases to central nervous system	892.15	23.24	292	26461	17250	90584444
Platelet count decreased	471.68	23.24	361	26392	136608	90465086
Thrombocytopenia	465.70	23.24	428	26325	208297	90393397
Myelosuppression	394.31	23.24	227	26526	53364	90548330
Ejection fraction decreased	363.23	23.24	170	26583	26083	90575611
Neuropathy peripheral	357.12	23.24	307	26446	136663	90465031
Metastases to lymph nodes	323.86	23.24	124	26629	11565	90590129
Metastases to lung	276.48	23.24	121	26632	15870	90585824
Epistaxis	255.25	23.24	207	26546	84918	90516776
Palmar-plantar erythrodysaesthesia syndrome	222.95	23.24	125	26628	27898	90573796
Nodular regenerative hyperplasia	204.02	23.24	46	26707	637	90601057
Metastases to bone	198.11	23.24	112	26641	25393	90576301
Portal hypertension	190.36	23.24	66	26687	4635	90597059
Malignant neoplasm progression	176.01	23.24	186	26567	106684	90495010
Metastases to skin	151.92	23.24	46	26707	2094	90599600
Cardiotoxicity	136.91	23.24	67	26686	11322	90590372
Radiation necrosis	135.94	23.24	33	26720	640	90601054
Vascular device infection	133.85	23.24	67	26686	11885	90589809
Breast cancer metastatic	132.71	23.24	72	26681	15060	90586634
Neoplasm progression	130.76	23.24	107	26646	44379	90557315
Polyneuropathy	126.54	23.24	76	26677	19265	90582429
Metastases to liver	121.61	23.24	86	26667	28721	90572973
Skin fissures	121.41	23.24	76	26677	20733	90580961
Joint swelling	120.56	23.24	7	26746	503293	90098401
Aspartate aminotransferase increased	120.15	23.24	150	26603	102787	90498907
Hepatopulmonary syndrome	116.53	23.24	21	26732	81	90601613
Metastasis	111.15	23.24	48	26705	6089	90595605
Pneumonitis	106.83	23.24	95	26658	44075	90557619
Spider naevus	104.75	23.24	21	26732	158	90601536
Alanine aminotransferase increased	103.76	23.24	150	26603	118188	90483506
Breast cancer recurrent	102.82	23.24	44	26709	5459	90596235
Hepatotoxicity	101.85	23.24	94	26659	45748	90555946
Recurrent cancer	101.40	23.24	35	26718	2424	90599270
Pleural effusion	101.19	23.24	144	26609	111847	90489847
Drug hypersensitivity	98.42	23.24	11	26742	463598	90138096
Brain oedema	97.68	23.24	62	26691	17323	90584371
Rheumatoid arthritis	93.52	23.24	3	26750	362611	90239083
Blood lactate dehydrogenase increased	92.65	23.24	70	26683	25862	90575832
Left ventricular dysfunction	89.17	23.24	55	26698	14614	90587080
Systemic lupus erythematosus	86.72	23.24	5	26748	361891	90239803
Blood bilirubin increased	84.88	23.24	83	26670	43387	90558307
Abdominal discomfort	84.11	23.24	19	26734	477309	90124385
Streptococcal sepsis	81.60	23.24	33	26720	3551	90598143
Diarrhoea	80.99	23.24	513	26240	938677	89663017
Nail bed inflammation	79.59	23.24	27	26726	1774	90599920
Arthropathy	79.47	23.24	8	26745	366234	90235460
Breast disorder	78.94	23.24	30	26723	2737	90598957
Nasal mucosal disorder	78.78	23.24	27	26726	1830	90599864
Interstitial lung disease	77.64	23.24	104	26649	76301	90525393
Gamma-glutamyltransferase increased	76.98	23.24	74	26679	37878	90563816
Pseudomonal sepsis	75.79	23.24	33	26720	4269	90597425
Excessive eye blinking	74.38	23.24	24	26729	1348	90600346
Blood alkaline phosphatase increased	74.36	23.24	81	26672	47998	90553696
Paronychia	72.73	23.24	39	26714	7967	90593727
Condition aggravated	72.58	23.24	43	26710	595502	90006192
Blood uric acid decreased	72.16	23.24	21	26732	832	90600862
Neutropenia	71.24	23.24	185	26568	224719	90376975
Breast neoplasm	71.06	23.24	24	26729	1556	90600138
Treatment failure	70.42	23.24	5	26748	303923	90297771
Product dose omission issue	69.95	23.24	4	26749	291683	90310011
Swelling	69.31	23.24	19	26734	419039	90182655
Non-cirrhotic portal hypertension	68.47	23.24	17	26736	363	90601331
Nausea	67.67	23.24	558	26195	1109758	89491936
Pericarditis	67.02	23.24	3	26750	270148	90331546
Metastases to spine	66.88	23.24	29	26724	3714	90597980
Hypokalaemia	66.37	23.24	130	26623	130986	90470708
Axillary pain	65.62	23.24	25	26728	2296	90599398
Eosinophil percentage increased	64.35	23.24	20	26733	994	90600700
Radiation pneumonitis	63.49	23.24	23	26730	1835	90599859
Tumour marker increased	63.39	23.24	32	26721	5775	90595919
Constipation	63.06	23.24	204	26549	280191	90321503
Mucosal inflammation	62.50	23.24	81	26672	57544	90544150
Gingival bleeding	61.75	23.24	44	26709	14859	90586835
Ascites	59.59	23.24	72	26681	47668	90554026
Hyperchlorhydria	58.84	23.24	22	26731	1919	90599775
Telangiectasia	58.25	23.24	20	26733	1363	90600331
Hepatic function abnormal	58.09	23.24	70	26683	46218	90555476
Hemianopia	57.34	23.24	22	26731	2060	90599634
Peripheral sensory neuropathy	57.03	23.24	35	26718	9215	90592479
Anaemia	56.67	23.24	230	26523	352572	90249122
Haematotoxicity	56.58	23.24	39	26714	12496	90589198
Sinusitis	55.89	23.24	16	26737	343072	90258622
Wound	55.50	23.24	11	26742	302969	90298725
Musculoskeletal stiffness	53.83	23.24	11	26742	296521	90305173
Impaired healing	53.82	23.24	4	26749	234195	90367499
Hand dermatitis	51.97	23.24	15	26738	577	90601117
Lymphangiosis carcinomatosa	50.86	23.24	19	26734	1653	90600041
Discomfort	50.16	23.24	10	26743	274325	90327369
Blood creatinine decreased	48.93	23.24	28	26725	6487	90595207
Drug interaction	48.66	23.24	11	26742	276442	90325252
Hyperbilirubinaemia	48.41	23.24	37	26716	13899	90587795
Maternal exposure during pregnancy	48.21	23.24	23	26730	360040	90241654
Performance status decreased	47.93	23.24	24	26729	4256	90597438
Death	47.92	23.24	263	26490	456288	90145406
Microvascular coronary artery disease	47.57	23.24	12	26741	274	90601420
Dyschezia	47.31	23.24	21	26732	2844	90598850
Wheezing	47.21	23.24	7	26746	238073	90363621
Candida infection	46.87	23.24	54	26699	34003	90567691
Radiation skin injury	46.69	23.24	16	26737	1084	90600610
Lymphoedema	46.65	23.24	36	26717	13717	90587977
Vessel puncture site bruise	46.55	23.24	13	26740	443	90601251
Asthma	46.04	23.24	8	26745	242152	90359542
Product use in unapproved indication	45.75	23.24	21	26732	336215	90265479
Therapeutic product effect decreased	45.09	23.24	13	26740	277558	90324136
Urticaria	44.99	23.24	18	26735	312716	90288978
Electric shock sensation	44.71	23.24	17	26736	1553	90600141
Transaminases increased	44.64	23.24	55	26698	37137	90564557
Splenomegaly	44.20	23.24	34	26719	12890	90588804
Nail dystrophy	43.86	23.24	16	26737	1302	90600392
Asthenopia	43.79	23.24	20	26733	2894	90598800
Varicose vein	43.33	23.24	27	26726	7300	90594394
Ejection fraction	43.17	23.24	20	26733	2991	90598703
Mobility decreased	42.12	23.24	11	26742	250723	90350971
Carcinoembryonic antigen increased	41.31	23.24	18	26735	2332	90599362
Arteriovenous malformation	41.28	23.24	16	26737	1539	90600155
Drug intolerance	41.01	23.24	43	26710	447548	90154146
Febrile neutropenia	40.93	23.24	121	26632	158228	90443466
Lacrimation increased	40.80	23.24	45	26708	27017	90574677
Metastases to pleura	40.36	23.24	17	26736	2027	90599667
Therapeutic product effect incomplete	40.10	23.24	5	26748	193891	90407803
Lymphadenopathy	40.05	23.24	58	26695	45717	90555977
Intracranial pressure increased	40.03	23.24	25	26728	6786	90594908
Dry skin	39.41	23.24	83	26670	87990	90513704
Gastrointestinal toxicity	39.33	23.24	28	26725	9439	90592255
Confusional state	38.99	23.24	34	26719	386171	90215523
Seizure	38.85	23.24	116	26637	152513	90449181
Varices oesophageal	38.85	23.24	20	26733	3759	90597935
Tumour pain	38.29	23.24	16	26737	1871	90599823
Hypertransaminasaemia	38.17	23.24	34	26719	15791	90585903
Skin toxicity	37.63	23.24	24	26729	6755	90594939
Pituitary tumour	37.44	23.24	13	26740	916	90600778
Cellulitis	36.23	23.24	82	26671	91255	90510439
Metastases to meninges	36.20	23.24	19	26734	3716	90597978
Folate deficiency	36.19	23.24	18	26735	3147	90598547
Injection site extravasation	35.92	23.24	26	26727	8993	90592701
Vulvovaginal candidiasis	35.43	23.24	19	26734	3881	90597813
Neutrophil count decreased	35.05	23.24	70	26683	71462	90530232
Hydrocephalus	34.89	23.24	22	26731	6072	90595622
Vulvovaginal pain	34.60	23.24	18	26735	3456	90598238
Sleep disorder	34.59	23.24	8	26745	198022	90403672
Eastern Cooperative Oncology Group performance status worsened	34.57	23.24	15	26738	1924	90599770
Cardiac dysfunction	34.01	23.24	18	26735	3579	90598115
Hiccups	33.98	23.24	17	26736	3009	90598685
Hepatic cirrhosis	33.55	23.24	64	26689	63189	90538505
Tumour haemorrhage	33.46	23.24	15	26738	2079	90599615
Inappropriate schedule of product administration	33.22	23.24	3	26750	149930	90451764
Venoocclusive liver disease	32.73	23.24	21	26732	5972	90595722
Anal erythema	32.65	23.24	9	26744	292	90601402
Osteoarthritis	32.09	23.24	9	26744	195721	90405973
Neoplasm	31.72	23.24	24	26729	8879	90592815
Bone marrow infiltration	30.94	23.24	11	26742	831	90600863
Depression	30.89	23.24	26	26727	300575	90301119
Bone pain	30.78	23.24	61	26692	61922	90539772
Injury	30.68	23.24	10	26743	197339	90404355
Nail infection	30.52	23.24	15	26738	2557	90599137
Central nervous system infection	30.45	23.24	11	26742	870	90600824
Type 2 diabetes mellitus	30.38	23.24	11	26742	203233	90398461
Mucosal dryness	30.38	23.24	16	26737	3151	90598543
Hyperaesthesia	29.88	23.24	25	26728	10677	90591017
Fall	29.71	23.24	61	26692	481749	90119945
Nail bed bleeding	29.54	23.24	9	26744	418	90601276
Myalgia	29.53	23.24	116	26637	175009	90426685
Biliary sepsis	29.25	23.24	11	26742	975	90600719
Device related infection	29.13	23.24	37	26716	25749	90575945
Pulmonary mass	28.96	23.24	39	26714	28733	90572961
Drug ineffective	28.39	23.24	267	26486	1384031	89217663
Metastases to soft tissue	28.04	23.24	8	26745	295	90601399
Hormone receptor positive breast cancer	27.93	23.24	10	26743	771	90600923
Neurotoxicity	27.80	23.24	33	26720	21434	90580260
Cough	27.63	23.24	195	26558	368767	90232927
Gait inability	27.47	23.24	5	26748	146451	90455243
Hepatic failure	27.26	23.24	45	26708	39683	90562011
Dysmenorrhoea	27.08	23.24	17	26736	4655	90597039
Pain	26.98	23.24	178	26575	996163	89605531
Arthritis	26.86	23.24	8	26745	167307	90434387
Hypersensitivity	26.83	23.24	59	26694	454618	90147076
Poor peripheral circulation	26.80	23.24	16	26737	4009	90597685
Water intoxication	26.67	23.24	9	26744	582	90601112
Weight increased	26.54	23.24	52	26701	417875	90183819
Breast pain	26.36	23.24	23	26730	10395	90591299
Hypothalamo-pituitary disorder	26.32	23.24	13	26740	2239	90599455
Nail bed tenderness	26.29	23.24	8	26745	370	90601324
Paravenous drug administration	26.28	23.24	4	26749	3	90601691
Axillary vein thrombosis	26.05	23.24	8	26745	382	90601312
Lymphocyte count decreased	25.82	23.24	41	26712	35009	90566685
Extravasation	25.70	23.24	14	26739	2950	90598744
Left ventricular dilatation	25.63	23.24	9	26744	656	90601038
Gastric varices	25.58	23.24	7	26746	221	90601473
Dental fistula	25.47	23.24	9	26744	668	90601026
Pleural neoplasm	25.26	23.24	8	26745	423	90601271
Bronchitis	25.12	23.24	7	26746	152920	90448774
Red cell distribution width increased	25.12	23.24	24	26729	12183	90589511
Conjunctivitis	25.07	23.24	35	26718	26671	90575023
Intracranial tumour haemorrhage	24.86	23.24	7	26746	246	90601448
Dermatitis acneiform	24.59	23.24	18	26735	6336	90595358
Skin mass	24.22	23.24	19	26734	7411	90594283
Adverse drug reaction	24.15	23.24	3	26750	116698	90484996
Subcapsular hepatic haematoma	24.12	23.24	4	26749	8	90601686
Hepatic lesion	24.08	23.24	17	26736	5656	90596038
Pneumothorax	24.06	23.24	29	26724	19138	90582556
Eosinophil count increased	23.72	23.24	24	26729	13057	90588637
Blood phosphorus decreased	23.51	23.24	16	26737	5018	90596676
Radical mastectomy	23.51	23.24	4	26749	10	90601684
Pneumonia	23.27	23.24	289	26464	637770	89963924
Scintillating scotoma	23.27	23.24	6	26747	150	90601544

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paranasal sinus discomfort	54.89	45.41	10	537	1187	42619601
Therapy partial responder	46.46	45.41	15	532	20006	42600782

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to central nervous system	668.28	22.52	231	23185	22586	110543297
Disease progression	563.83	22.52	443	22973	243591	110322292
Myelosuppression	338.31	22.52	224	23192	94116	110471767
Platelet count decreased	309.73	22.52	308	23108	230135	110335748
Metastases to lymph nodes	297.39	22.52	114	23302	14918	110550965
Thrombocytopenia	274.69	22.52	353	23063	348532	110217351
Ejection fraction decreased	267.10	22.52	143	23273	40737	110525146
Neuropathy peripheral	265.86	22.52	253	23163	179024	110386859
Metastases to lung	210.04	22.52	101	23315	22962	110542921
Metastases to bone	180.72	22.52	101	23315	31271	110534612
Palmar-plantar erythrodysaesthesia syndrome	163.07	22.52	104	23312	40921	110524962
Epistaxis	161.62	22.52	167	23249	130205	110435678
Metastases to skin	145.74	22.52	42	23374	2257	110563626
Nodular regenerative hyperplasia	131.66	22.52	36	23380	1595	110564288
Radiation necrosis	128.67	22.52	31	23385	823	110565060
Vascular device infection	128.55	22.52	65	23351	16447	110549436
Breast cancer metastatic	126.76	22.52	57	23359	11124	110554759
Malignant neoplasm progression	125.22	22.52	169	23247	174398	110391485
Polyneuropathy	121.89	22.52	79	23337	31933	110533950
Portal hypertension	117.30	22.52	50	23366	8587	110557296
Skin fissures	109.79	22.52	67	23349	24391	110541492
Hepatopulmonary syndrome	102.04	22.52	20	23396	192	110565691
Neoplasm progression	95.26	22.52	91	23325	64504	110501379
Cardiotoxicity	93.54	22.52	53	23363	16828	110549055
Metastases to liver	91.77	22.52	69	23347	35317	110530566
Breast disorder	89.85	22.52	29	23387	2285	110563598
Nail bed inflammation	89.39	22.52	28	23388	2002	110563881
Nasal mucosal disorder	87.23	22.52	27	23389	1856	110564027
Aspartate aminotransferase increased	84.39	22.52	134	23282	159802	110406081
Nausea	84.07	22.52	496	22920	1235194	109330689
Left ventricular dysfunction	82.20	22.52	55	23361	23438	110542445
Streptococcal sepsis	81.13	22.52	33	23383	5039	110560844
Diarrhoea	79.14	22.52	460	22956	1139045	109426838
Hepatotoxicity	76.32	22.52	80	23336	63320	110502563
Spider naevus	76.25	22.52	15	23401	147	110565736
Blood lactate dehydrogenase increased	76.11	22.52	68	23348	44266	110521617
Alanine aminotransferase increased	74.56	22.52	137	23279	183636	110382247
Joint swelling	74.28	22.52	5	23411	442840	110123043
Paronychia	72.99	22.52	39	23377	11042	110554841
Pleural effusion	70.23	22.52	131	23285	177578	110388305
Drug interaction	70.19	22.52	11	23405	500172	110065711
Lymphoedema	69.84	22.52	42	23374	14887	110550996
Constipation	69.27	22.52	199	23217	357587	110208296
Recurrent cancer	67.82	22.52	26	23390	3397	110562486
Brain oedema	66.26	22.52	54	23362	31044	110534839
Metastasis	65.68	22.52	33	23383	8234	110557649
Gamma-glutamyltransferase increased	64.40	22.52	72	23344	61237	110504646
Axillary pain	63.53	22.52	23	23393	2563	110563320
Blood uric acid decreased	63.27	22.52	20	23396	1473	110564410
Pseudomonal sepsis	62.87	22.52	33	23383	9013	110556870
Excessive eye blinking	62.80	22.52	21	23395	1849	110564034
Drug hypersensitivity	61.46	22.52	11	23405	454079	110111804
Tumour marker increased	61.21	22.52	27	23389	5033	110560850
Blood alkaline phosphatase increased	60.71	22.52	75	23341	70860	110495023
Non-cirrhotic portal hypertension	58.16	22.52	16	23400	725	110565158
Eosinophil percentage increased	58.07	22.52	19	23397	1563	110564320
Hemianopia	57.59	22.52	22	23394	2846	110563037
Condition aggravated	57.57	22.52	43	23373	734793	109831090
Varicose vein	53.08	22.52	27	23389	6913	110558970
Hyperchlorhydria	52.20	22.52	19	23397	2150	110563733
Rheumatoid arthritis	51.36	22.52	3	23413	299610	110266273
Metastases to spine	50.46	22.52	24	23392	5319	110560564
Nail dystrophy	50.18	22.52	16	23400	1212	110564671
Product dose omission issue	50.16	22.52	5	23411	321777	110244106
Ejection fraction	49.93	22.52	20	23396	2935	110562948
Candida infection	49.77	22.52	56	23360	47953	110517930
Lymphangiosis carcinomatosa	49.70	22.52	19	23397	2463	110563420
Vessel puncture site bruise	49.09	22.52	13	23403	509	110565374
Hand dermatitis	48.85	22.52	14	23402	737	110565146
Pneumonitis	48.69	22.52	70	23346	76461	110489422
Asthenopia	48.60	22.52	20	23396	3144	110562739
Microvascular coronary artery disease	47.41	22.52	12	23404	392	110565491
Telangiectasia	47.25	22.52	17	23399	1860	110564023
Fatigue	46.59	22.52	426	22990	1215532	109350351
Blood creatinine decreased	46.12	22.52	27	23389	9110	110556773
Hypokalaemia	45.96	22.52	112	23304	182336	110383547
Radiation skin injury	45.71	22.52	16	23400	1616	110564267
Interstitial lung disease	45.69	22.52	95	23321	139239	110426644
Gingival bleeding	45.56	22.52	36	23380	19803	110546080
Radiation pneumonitis	44.75	22.52	21	23395	4515	110561368
Skin toxicity	44.65	22.52	29	23387	11754	110554129
Vulvovaginal candidiasis	44.55	22.52	19	23397	3266	110562617
Peripheral sensory neuropathy	44.30	22.52	33	23383	16647	110549236
Treatment failure	44.02	22.52	4	23412	277230	110288653
Blood bilirubin increased	41.91	22.52	65	23351	75907	110489976
Gastrointestinal toxicity	41.17	22.52	27	23389	11121	110554762
Performance status decreased	40.76	22.52	23	23393	7243	110558640
Carcinoembryonic antigen increased	40.51	22.52	17	23399	2807	110563076
Drug ineffective	40.13	22.52	176	23240	1520364	109045519
Product use in unapproved indication	39.28	22.52	23	23393	447354	110118529
Arthropathy	38.80	22.52	7	23409	287515	110278368
Breast cancer recurrent	38.54	22.52	18	23398	3828	110562055
Urticaria	38.49	22.52	10	23406	318847	110247036
Injection site extravasation	38.46	22.52	25	23391	10144	110555739
Mucosal inflammation	38.11	22.52	71	23345	96070	110469813
Pituitary tumour	37.86	22.52	13	23403	1240	110564643
Seizure	37.06	22.52	117	23299	221068	110344815
Systemic lupus erythematosus	37.02	22.52	5	23411	254333	110311550
Tumour pain	36.43	22.52	16	23400	2951	110562932
Abdominal discomfort	36.38	22.52	19	23397	393839	110172044
Bone pain	36.30	22.52	56	23360	65077	110500806
Electric shock sensation	35.79	22.52	14	23402	1930	110563953
Nail infection	35.77	22.52	15	23401	2473	110563410
Arteriovenous malformation	35.74	22.52	14	23402	1937	110563946
Urinary tract infection	35.52	22.52	150	23266	326132	110239751
Lacrimation increased	35.36	22.52	38	23378	30912	110534971
Pericarditis	35.22	22.52	3	23413	219111	110346772
Acute kidney injury	35.20	22.52	50	23366	635380	109930503
Metastases to pleura	34.98	22.52	14	23402	2049	110563834
Ascites	34.88	22.52	67	23349	92741	110473142
Bone marrow infiltration	34.20	22.52	11	23405	857	110565026
Hormone receptor positive breast cancer	34.17	22.52	10	23406	567	110565316
Toxicity to various agents	34.01	22.52	31	23385	480524	110085359
Asthma	33.97	22.52	6	23410	250285	110315598
Metastases to meninges	33.64	22.52	18	23398	5110	110560773
Vulvovaginal pain	33.63	22.52	15	23401	2869	110563014
Therapeutic product effect incomplete	33.54	22.52	4	23412	223801	110342082
Eastern Cooperative Oncology Group performance status worsened	33.22	22.52	15	23401	2954	110562929
Folate deficiency	33.17	22.52	17	23399	4421	110561462
Wheezing	32.78	22.52	7	23409	255223	110310660
Dry skin	32.51	22.52	71	23345	107582	110458301
Swelling	32.32	22.52	17	23399	351024	110214859
Hypertransaminasaemia	31.70	22.52	32	23384	24223	110541660
Haematotoxicity	31.63	22.52	30	23386	21052	110544831
Anaemia	31.56	22.52	211	23205	546875	110019008
Cough	30.30	22.52	184	23232	461457	110104426
Atrial fibrillation	30.11	22.52	6	23410	229636	110336247
Confusional state	30.00	22.52	33	23383	468647	110097236
Musculoskeletal stiffness	29.78	22.52	11	23405	279811	110286072
Dental fistula	29.56	22.52	9	23407	585	110565298
Cellulitis	29.24	22.52	75	23341	125941	110439942
Fall	29.15	22.52	52	23364	603430	109962453
Hyperbilirubinaemia	28.80	22.52	34	23382	30637	110535246
Nail bed tenderness	28.79	22.52	8	23408	376	110565507
Hydrocephalus	28.61	22.52	21	23395	10354	110555529
Poor peripheral circulation	28.28	22.52	15	23401	4182	110561701
Pleural neoplasm	28.20	22.52	8	23408	406	110565477
Pulmonary mass	28.06	22.52	37	23379	37264	110528619
Tumour haemorrhage	27.80	22.52	16	23400	5229	110560654
Conjunctivitis	27.74	22.52	35	23381	33757	110532126
Hypothalamo-pituitary disorder	27.54	22.52	13	23403	2833	110563050
Dysmenorrhoea	27.48	22.52	14	23402	3596	110562287
Nail discolouration	27.39	22.52	14	23402	3621	110562262
Discomfort	27.34	22.52	6	23410	214701	110351182
Breast pain	27.04	22.52	20	23396	9980	110555903
Central nervous system infection	26.78	22.52	11	23405	1721	110564162
Therapy partial responder	26.71	22.52	36	23380	37025	110528858
Drug intolerance	26.70	22.52	28	23388	406484	110159399
Nail bed bleeding	26.33	22.52	9	23407	847	110565036
Biliary sepsis	26.12	22.52	11	23405	1832	110564051
Tumour marker abnormal	25.96	22.52	7	23409	294	110565589
Transaminases increased	25.35	22.52	47	23369	63343	110502540
Therapeutic product effect decreased	25.33	22.52	10	23406	244306	110321577
Water intoxication	25.33	22.52	9	23407	950	110564933
Spinal pain	25.25	22.52	25	23391	18490	110547393
Lymphadenopathy	25.11	22.52	47	23369	63788	110502095
Sinusitis	24.98	22.52	16	23400	296672	110269211
Hepatic function abnormal	24.84	22.52	57	23359	89238	110476645
Breast neoplasm	24.47	22.52	9	23407	1049	110564834
Mobility decreased	24.16	22.52	10	23406	237412	110328471
Mean cell haemoglobin concentration decreased	24.05	22.52	15	23401	5667	110560216
Nasal dryness	24.00	22.52	15	23401	5691	110560192
Metastases to soft tissue	23.85	22.52	8	23408	711	110565172
Wound	23.65	22.52	10	23406	234427	110331456
Weight decreased	23.17	22.52	174	23242	467883	110098000
Back pain	23.15	22.52	146	23270	370850	110195033
Catheter site inflammation	23.08	22.52	9	23407	1231	110564652
Scintillating scotoma	22.96	22.52	6	23410	223	110565660
Skin mass	22.94	22.52	18	23398	9798	110556085
Splenomegaly	22.74	22.52	27	23389	24471	110541412

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FD03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D000922	Immunotoxins
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D050257	Tubulin Modulators
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors 5 drugs

margetuximabpertuzumabtrastuzumabtrastuzumab deruxtecanzanidatamab-hrii

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
HER2-positive carcinoma of breast	indication	427685000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
SE2KH7T06F	UNII
D09980	KEGG_DRUG
4032192	VUID
N0000186780	NUI
4032192	VANDF
C2935436	UMLSCUI
CHEBI:750159	CHEBI
CHEMBL1743082	ChEMBL_ID
DB05773	DRUGBANK_ID
CHEMBL1201585	ChEMBL_ID
9295	INN_ID
6928	IUPHAR_LIGAND_ID
1371041	RXNORM
199194	MMSL
29308	MMSL
d08069	MMSL
014910	NDDF
702836004	SNOMEDCT_US
896752005	SNOMEDCT_US
D000080044	MESH_DESCRIPTOR_UI
CHEMBL1743037	ChEMBL_ID
SE2KH7T06F	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-087	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	36 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-088	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	36 sections